Pharmacy Spring 2023 Preceptor Continuing Education Seminar - Clinical and Legal Considerations for Cannabis_Online
Use of medical marijuana (cannabis) is becoming more common, and healthcare providers need to understand the pharmacology behind its use, the clinical concerns, safety, as well as approved medical conditions. Legal implications exist as well, and providers need to know the practical considerations with risks and benefits of medical cannabis.
Nurse, Nurse Practitioner, Pharmacist, Physician, and Physician Assistant
At the conclusion of this activity, participants will be able to:
- Describe key features of the endocannabinoid system and cannabis pharmacology, and non-phytocannabinoid constitutes of cannabis; including pharmacokinetics and formulations.
- Describe adverse effects of cannabis use and distinguish clinical concerns associated with selected interactions involving medical marijuana use.
- Discuss best practices in patient evaluation, medical marijuana product choice, dosage and therapeutic monitoring based on the patient’s serious medical condition
- Discuss risk versus benefits including recognition of potential drug interactions, side effects, potential use disorder.
- Explain the status of cannabis as a controlled substance under U.S. federal law and the provisions of Pennsylvania's Medical Marijuana Act of 2016.
- Review practice implications of the most current proposed USP cannabis monograph.
- Have informed discussions with patients about the risks and benefits of medical cannabis for the Pennsylvania approved serious medical conditions
- Susan Skledar, RPh, MPH, FASHP - Director of Experiential Learning, Professor, Department of Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy
- Amy Seybert, PharmD - Chair of the Department of Pharmacy and Therapeutics as well as the Pharmacy Residency Administrator at UPMC
Dr. Seybert disclosed she completed 2 advisory meetings with Pfizer.
- Christine Roussel, PharmD, BCOP, BCSCP - Senior Executive Director, Pharmacy, Laboratory and Medical Research, Doylestown Health
Authors disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above.
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Pharmacy Education activity is 2.0 contact hours.
- Drug therapy/ disease state management designation: JA4008223-0000-23-191-H01-P
- Law designation: JA4008223-0000-23-192-H03-P
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
- 2.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.
- 2.00 Opioid Education
- 2.00 Attendance
- 2.00 Opioid Education
Choose Register/Complete Course to complete the module.
First time Users: If you have never completed training on this website, please select register in the upper right hand corner of the webpage.
Returning Users: If you have completed training on this website, please log in in the upper right hand corner of the webpage.